# Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients

> **NCT06661148** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Epigenic Therapeutics, Inc** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Hepatitis B
- HBV (Hepatitis B Virus)

## Interventions

- **DRUG:** EPI-003

## Key facts

- **NCT ID:** NCT06661148
- **Lead sponsor:** Epigenic Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06661148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06661148, "Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06661148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*